Pivot Park welcomes 60th tenant

Biopharmaceutical Life Science campus Pivot Park officially welcomed Citryll as the 60th tenant.

“We are very pleased to have Citryll onboard our community, and that they have chosen Pivot Park as the best place to establish their business.” Says Brigitte Drees, CEO of Pivot Park. “Our campus is becoming increasingly interesting because of the ongoing growth in number of companies, people, knowledge and interactions reinforcing each other. With the team of Citryll we see an exciting entrepreneurial spirit that is contagious. For sure a contribution to the lively community here at the campus.”

“Pivot Park is located at the former Merck R&D sites, the birthplace of Keytruda among some of the approved medicines. Pivot Park houses promising product development companies and valuable pharmaceutical service organizations, forming an attractive ecosystem for drug discovery and drug development” says CEO Helmuth van Es.

Pivot Park is Europe’s most exciting campus for biopharmaceutical innovation and discovery, based in Oss, the Netherlands. It combines lab and office spaces of all sizes with high-quality pharmaceutical R&D facilities, GMP-qualified pilot plants, an ultra-High Throughput Screening Centre, on-site analytical support and a well-equipped Open Access laboratory.

The result is a dynamic and uniquely pharma-based knowledge community that provides start-ups and scale-ups with the entrepreneurial support, equipment and talent pool they need to excel, accelerate and grow. Situated at the homeland of the Dutch Pharmaceutical industry, Pivot Park is perfectly placed to win talent, with room for growth and countryside to enjoy. 

Citryll BV is a private pharmaceutical company that is taking a new approach to treat autoimmune and other human diseases like lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis. Citryll is dedicated to the development and commercialization of therapeutics that target NETosis and NETs. Citryll was founded by ModiQuest B.V., originator of the tACPA patents, Helmuth van Es, CEO Citryll (co-founder of Audion Therapeutics, Galapagos, Antabio and Effecta Pharma), and Renato Chirivi, CSO Citryll and co-inventor of tACPA antibodies.

Source: Pivot Park